



THC BIOMED INTL LTD.
P.O. Box 20033 Towne Centre
Kelowna, B.C. V1Y 9H2
www.thcbiomed.com

THC Draws Down \$500,000 in Two Tranches from Capital Commitment

THC.CSE

THCBF - OTC

TFHC.F

Vancouver, B.C. – (October 3, 2017) THC BioMed Intl Ltd. (CSE: THC), ("THC" or the "Company") is pleased to announce that it intends to draw down a total of \$500,000 in two tranches from its existing capital commitment agreement with Alumina Partners (Ontario) Ltd. ("Alumina") is in the process of completing a private placement totaling \$500,000. The first tranche of \$250,000 closed on October 2, 2017 and the process for closing the second tranche of another \$250,000 began today.

The first tranche closed on October 2, 2017 for total funds of \$250,000.12.

In consideration for the \$250,000.12, THC issued to Alumina 403,226 units at a price of \$0.62 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share of the Company for a period of 36 months from closing at a price of \$0.96 per share.

THC also began the process of closing the second tranche today. THC intends to close this second tranche within the next five business days, for proceeds of approximately \$250,000.42.

When the \$250,000.42 is received, THC intends to issue to Alumina 359,196 units at a price of \$0.696 per unit. Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share of the Company for a period of 36 months from closing at a price of \$1.0875 per share.

The investor in this private placement is Alumina Partners (Ontario) Ltd. and it is investing in THC pursuant to the capital commitment agreement between the companies that was announced by THC on August 11, 2017.

The proceeds of the Private Placement will be used for general working capital, including the ramp up of existing production and sales operations and the exploration of new opportunities.

About THC

THC's vision is to be on the leading edge of scientific research, development of products and services related to the medical cannabis industry while creating a standard of excellence. As the industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry.

Please visit our website for a more detailed description of our business and services available.
www.thcbiomed.com

President and CEO:

John Miller
THC Biomed Intl Ltd.
T: 1-844-THCMEDS
E: info@thcbiomed.com

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. In some cases, you can identify forward-looking statements by the use of words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that: (a) THC will complete a second tranche consisting of 359,196 units at a price of \$0.696 per unit, (b) the investments will be used for the stated purposes; (b) THC's vision is to be on the leading edge of scientific research, development of products and services related to the medical cannabis industry while creating a standard of excellence; (c) as the medical marijuana industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis; and (d) THC will be in the forefront of this rapidly growing industry.

THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.